Reports of 5-ASA-associated pancreatitis from the FDA adverse event reporting databases

被引：0
|
作者：
Ruggieri, Alexander P.
Kanumalla, Anju
Watson, John F.
机构：
来源：
GASTROENTEROLOGY | 2007年 / 132卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A343 / A343
页数：1
相关论文
共 50 条
  • [41] Fatal reports in intramuscular vs oral antipsychotics in the FDA adverse event reporting system (AERS)
    Sorsaburu, Sebastian
    Chilcott, Karen E.
    DeLisle, F. Patrick
    Hornbuckle, Kenneth
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S222 - S222
  • [42] Pediatric drug-induced anaphylaxis reports in the FDA Adverse Event Reporting System (FAERS)
    Brameli, Anna
    Yuan, Irene H.
    Phillips, Elizabeth J.
    Stone Jr, Cosby A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (09):
  • [43] Evaluating Reports of Pancreatic Malignancy and Liraglutide: A Pharmacovigilance Study of the FDA Adverse Event Reporting System
    Alvarez, Carlos A.
    Teng, Chengwen
    Mansi, Ishak
    DIABETES, 2020, 69
  • [44] Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases
    Mukai, Ririka
    Hasegawa, Shiori
    Umetsu, Ryogo
    Nakao, Satoshi
    Shimada, Kazuyo
    Uranishi, Hiroaki
    Masuta, Mayuko
    Suzuki, Honami
    Nishibata, Yuri
    Nakamura, Mitsuhiro
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (02) : 285 - 291
  • [45] Missing data in FDA adverse event reporting systems
    Smith, Sheila Weiss
    Gogolak, Victor V.
    Deshpande, Gaurav
    Chung, Stephanie
    Mehta, Shekhar H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S72 - S72
  • [46] Spontaneous reporting of rare events associated with atypical antipsychotics using the FDA adverse event reporting system
    Emechebe, Nnadozie
    Mukhtar, Fahad
    Scheer, Darren
    Patel, Arshiya
    Wadhawan, Abhishek
    Schwartz, Skai
    Zgibor, Janice
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 345 - 346
  • [47] An evaluation of the FDA adverse event reporting system and the potential for reporting bias
    Monnot, Andrew D.
    Fung, Ernest S.
    Compoginis, Goli S.
    Towle, Kevin M.
    JOURNAL OF COSMETIC DERMATOLOGY, 2021, 20 (06) : 1849 - 1854
  • [48] Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database
    Caldito, Natalia Gonzalez
    Shirani, Afsaneh
    Salter, Amber
    Stuve, Olaf
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (07) : 1066 - 1076
  • [49] Adverse event profile differences between rituximab and ocrelizumab: findings from the fda adverse event reporting database
    Caldito, N. Gonzalez
    Shirani, A.
    Salter, A.
    Stuve, O.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 257 - 257
  • [50] Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
    Pan, Xianglin
    Xiao, Xiangtian
    Ding, Yiling
    Shu, Yamin
    Zhang, Wenting
    Huang, Liu
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345